Cyclacel (Berkeley Heights, NJ) is a clinical-stage biopharmaceutical company developing innovative cancer medicines based on cell cycle, transcriptional regulation, and mitosis biology. Its aim is to build a diversified biopharma business based on a pipeline of novel drug candidates that address oncology and hematology indications. President and CEO Spiro Rombotis joined the company as its […]

New pharmacotherapies and novel approaches, such as gene therapy and cell therapy, are raising realistic hopes for patients with geographic atrophy, a condition that can lead to vision loss. “There has been a tremendous amount of clinical research looking at different therapeutic avenues for geographic atrophy, and we have had some prominent disappointments over the […]

In recent years, the field of DNA-modified cell therapies has experienced clinical advancements in patient outcomes specifically in late-stage cancer patients. Permanent changes to the genetic compositions in patients’ cells may lead to toxicities such as cytokine release syndrome, or the uncontrollable proliferation of DNA-modified cells. To address the irreversibility and lack of predictability of […]